Add BrightSurf on Google Email

Search results for “Gene therapy”

1,000+ results for "Gene therapy"

Vision improvement after gene therapy maintained at 1 year for inherited retinal blindness

Researchers have documented remarkable vision improvements in three young adults with Leber Congenital Amaurosis after receiving gene therapy. The patients continue to experience increased sensitivity to light, and one patient was able to read an illuminated clock for the first time at 1 year after treatment.

SourceUniversity of Pennsylvania School of Medicine·JournalNew England Journal of Medicine·DateAug 12, 2009

Could science use the common cold to cure cystic fibrosis?

Researchers at University of North Carolina have discovered a new approach to delivering a corrected CF gene to lung cells using parainfluenza virus, which could potentially cure cystic fibrosis lung disease. The method has shown promise in laboratory models and may pave the way for future clinical trials.

SourcePLOS·JournalPLOS Biology·DateJul 20, 2009

Gene therapy for hemophilia A mice

Researchers at the University of Minnesota Medical School have successfully provided long-term expression of Factor VIII in hemophilia A mice using a new gene therapy approach, marking a promising step toward human clinical trials.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateJun 8, 2009

Simulated gene therapy

Scientists at the University of California, Berkeley and Los Alamos National Laboratory have developed a comprehensive numerical study of gene therapy. The research sheds light on the key factors that determine the success of dendrimers as gene delivery vehicles, including the charges of the dendrimers and their target cell membranes.

SourceAmerican Institute of Physics·JournalThe Journal of Chemical Physics·DateApr 29, 2009

A dead gene comes back to life in humans

Researchers have rediscovered a dormant human gene, IRGM, which was thought to be extinct for millions of years. The study, published in PLOS Genetics, reveals that the gene was resurrected through a complex series of structural events, suggesting its potential importance in fighting new or resistant infectious agents.

SourcePLOS·JournalPLOS Genetics·DateMar 5, 2009

Boosting its infectivity turns benign virus into good gene therapy carrier for cystic fibrosis

Scientists have turned a benign adeno-associated virus into a highly infectious form that can effectively deliver a gene to lung cells, potentially curing cystic fibrosis. The new strain was created by forcing evolution to increase infectivity several hundred-fold, overcoming previous limitations in gene therapy.

SourceUniversity of California - Berkeley·JournalProceedings of the National Academy of Sciences·DateFeb 16, 2009

Rituximab maintenance therapy improves survival in patients with relapsed follicular lymphoma

Patients with relapsed follicular lymphoma who continue on maintenance rituximab therapy after chemotherapy have better overall survival than those without treatment. Rituximab maintenance therapy was associated with a 40% improvement in overall survival relative to observation or retreatment.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateFeb 10, 2009

Early-stage gene transcription creates access to DNA

Researchers have discovered a novel mechanism in gene expression where non-coding RNAs create access to DNA, allowing transcriptional activation proteins to initiate gene expression. This process involves the transient synthesis of non-coding RNAs that unfurl tightly wound DNA, enabling gene expression.

SourceBoston College·JournalNature·DateOct 6, 2008

UF researchers develop improved gene therapy agent

Researchers at the University of Florida have developed a new version of the adeno-associated virus used in gene therapy that works more efficiently than current vectors. By replacing an amino acid on the surface of the virus, they were able to improve its ability to deliver genes into cells and reduce the risk of triggering an immune ...

SourceUniversity of Florida·JournalProceedings of the National Academy of Sciences·DateMay 19, 2008

JCI online early table of contents: April 15, 2008

New data shows that vectors derived from AAV5 can accommodate large genes, including those missing in a mouse model of recessive Stargardt disease. This breakthrough has implications for treating individuals with the disease, which is characterized by progressive loss of sight.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateApr 15, 2008

The yin and yang of genes for mood disorders

Researchers investigated how inheriting different combinations of gene variants impact depression risk in normal subjects. They found that the SLC6A4 serotonin transporter gene interacts with the BDNF gene to regulate emotion regulation system development, revealing individual genes are not isolated risks.

SourceMolecular Psychiatry·JournalMolecular Psychiatry·DateMar 12, 2008

Gene therapy 'trains' immune system to destroy brain cancer cells and reverses behavioral deficits

Researchers developed gene therapy approach that attracts and 'trains' immune system cells to destroy deadly brain cancer cells, promoting long-term immunity and restoring normal brain function. The therapy shows promise as a potential treatment for glioblastoma multiforme, the most common and deadly type of brain cancer.

SourceCedars-Sinai Medical Center·JournalMolecular Therapy·DateFeb 19, 2008

Debate over safety of gene therapy trials focuses on issue of informed consent

A series of commentaries in Human Gene Therapy explores key controversies surrounding patient recruitment and trial management in gene therapy trials. The authors discuss the challenges of patients comprehending lengthy and technical study descriptions and consent forms, and propose innovative strategies for improving informed consent.

Researchers find relief for chronic pain

Researchers at Mount Sinai School of Medicine have discovered a novel targeted gene therapy that simulates the pain-killing effect of opiate drugs, providing relief for more than three months after a single injection. The technique targets selectively the pain gate, avoiding unwanted side effects associated with opioid painkillers.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalProceedings of the National Academy of Sciences·DateJan 21, 2008